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Abstract
The presence of Foxp3
+ regulatory CD4
+ T cells in tumor lesions is considered one of the major causes of ineffective
immune response in cancer. It is not clear whether intratumoral Treg cells represent Treg cells pre-existing in healthy mice, or
arise from tumor-specific effector CD4
+ T cells and thus representing adaptive Treg cells. The generation of Treg population in
tumors could be further complicated by recent evidence showing that both in humans and mice the peripheral population
of Treg cells is heterogenous and consists of subsets which may differentially respond to tumor-derived antigens. We have
studied Treg cells in cancer in experimental mice that express naturally selected, polyclonal repertoire of CD4
+ T cells and
which preserve the heterogeneity of the Treg population. The majority of Treg cells present in healthy mice maintained a
stable suppressor phenotype, expressed high level of Foxp3 and an exclusive set of TCRs not used by naive CD4
+ T cells. A
small Treg subset, utilized TCRs shared with effector T cells and expressed a lower level of Foxp3. We show that response to
tumor-derived antigens induced efficient clonal recruitment and expansion of antigen-specific effector and Treg cells.
However, the population of Treg cells in tumors was dominated by cells expressing TCRs shared with effector CD4
+ T cells. In
contrast, Treg cells expressing an exclusive set of TCRs, that dominate in healthy mice, accounted for only a small fraction of
all Treg cells in tumor lesions. Our results suggest that the Treg repertoire in tumors is generated by conversion of effector
CD4
+ T cells or expansion of a minor subset of Treg cells. In conclusion, successful cancer immunotherapy may depend on
the ability to block upregulation of Foxp3 in effector CD4
+ T cells and/or selectively inhibiting the expansion of a minor Treg
subset.
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Introduction
The observation that tumor antigen-specific B and T cells are
activated in the course of tumor growth led to the presumption
that augmenting the immune system function will lead to the
eradication of tumor cells [1]. A multitude of cancer vaccines were
designed to harness potent effector functions and exquisite
specificity of the immune system to combat cancer. However,
immunotherapy protocols used so far have had only a limited
success what was attributed to poor recruitment of antigen specific
T cells into tumor lesions, inadequate stimulation by antigens
derived from tumor cells causing T cell anergy instead of T cell
activation and, in particular, to the presence of regulatory T cells
(Treg) expressing a transcription factor Foxp3 [2–4]. Despite their
importance for cancer immunity, the origin of Treg cells in tumors
remains little known.
Foxp3
+ Treg cells are a specific population of CD4
+ T
lymphocytes that control normal immune homeostasis and self-
tolerance [5]. Treg cells were identified as the major obstacle to
effective antitumor immunotherapy [6–8]. The abundance of
these cells in peripheral blood is increased in patients with multiple
types of cancer and their prevalence among tumor-infiltrating
lymphocytes correlated with poor clinical prognosis [9–11]. In
contrast, removal or inactivation of Treg cells led to enhanced
antitumor immune response and better efficacy of cancer vaccines
[12–15].
Two major subsets of Foxp3
+ Treg cells, natural and adaptive
Treg cells, were defined based on whether their suppressor function
is acquired during normal T cell development in the thymus or
following TCR stimulation in peripheral tissues or in vitro [16,17].
The lack of appropriate surface markers so far precluded the
analysis of the contribution of these subsets to the peripheral pool
of regulatory cells in healthy and tumor-bearing mice expressing
diverse, polyclonal TCR repertoire. Though the suppressor
function of the two Treg subsets was found similar in in vitro tests,
little is known how different are their homing properties, antigen
specificities and the ability to expand in vivo in response to antigen
stimulation and cytokines. The recent evidence that natural and
adaptive Treg subsets have different gene expression signature and
synergize to establish peripheral tolerance suggests that they serve
non-redundant functions [18,19]. In a recent report we have
shown that the level of Foxp3 expression and TCR repertoires
define two subsets of Treg cells in peripheral lymphoid organs [20].
The dominant fraction of peripheral Treg cells consistently
expresses high level of Foxp3 and a characteristic set of TCRs
not utilized by naive effector CD4
+ T cells. The second Treg subset
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only a small fraction of Treg cells, could up- or downregulate
Foxp3 when stimulated with antigen and utilized TCRs shared
with naive T cells. The modulation of Foxp3 expression was
dependent on the presence of cytokines, especially TGF-b, that
increased the fraction of cells upregulating Foxp3. This Treg subset
was able to efficiently expand in lymphopenic mice and in mice
undergoing immune response to antigen where it became a major
population of antigen-specific Treg cells. Since TCR repertoires
expressed by naive and Treg CD4
+ T cells show only a minimal
overlap, we postulate that Treg subset expressing TCRs shared
with naive cells represents adaptive Treg cells [20–22]. Our
findings corroborated recent report showing that two subsets of
peripheral Treg cells exist in mice not subject to any deliberate
antigen stimulation [23].
The heterogeneity of Treg population was also described in
humans. Two functional subsets of Foxp3
+ Treg cells with distinct
capacity to secrete IL-10 and TGF-b and using different
mechanisms of suppression were defined by expression of ICOS
[24]. High levels of ICOS was also expressed on melanoma tumor
infiltrating Treg cells producing high level of IL-10 [25]. In another
report the level of Foxp3 expression and CD45RA defined
populations of resting (CD45RA
+Foxp3
lo) and activated
(CD45RA
-Foxp3
hi)T reg cells and a population of cells (CD45RA
--
Foxp3
lo) able to produce IL-2 and IFN-c [26]. Resting Treg cells
convert into activated Treg cells and the relative proportions of
these subsets change in aged and diseased individuals. In
summary, both in humans and in mice peripheral Treg cells are
heterogenous and include subsets with different phenotypic and
functional characteristics that are subject to dynamic regulation. It
is not known what is the contribution of the recently identified Treg
subsets to the generation of Treg population in cancer, especially to
the population of Treg cells in tumor lesions.
While it is well established that upregulation of Foxp3 in effector
CD4
+ T cells leads to the generation of Treg cells, it is unclear what is
the contribution of converted and pre-existing Treg cells to the
population of Foxp3
+ T cells in tumors [27]. Experiments
investigating Treg cells in tumor-bearing mice that used adoptively
transferred effector and Treg cells expressing transgenic TCR specific
for tumor antigen have found that both subsets contribute to Treg
population [28]. However, it is not known how the number of
transferredcells affects the recruitment of antigen-specific effector and
Treg CD4
+ T cells into tumor draining lymph nodes and tumors and
if their migration, sensitivity to cytokines and/or conversion into Treg
cells is the same as CD4
+ T cells that naturally developed in recipient
mice. Moreover, since the majority of Treg cells express different
TCRs than effector T cells, it is unclear if Treg cells expressing the
same transgenic TCR as effector T cells used in these studies are
equivalent to the majority of Treg cells present in healthy mice.
To determine the origin of Treg cells in cancer, we used an
experimentalmodelinwhichimmuneresponse,ofbotheffectorand
Treg cells, to tumor-associated antigens can be characterized in mice
with a restricted and readily characterized CD4
+ T cell repertoire.
These mice undergo natural generation of a polyclonal CD4
+ T cell
repertoire with the set of TCR sequences that are used by the
majority of natural Treg cells distinct and readily differentiable from
the set of sequences used by effector T cells [22]. This allows us to
ask whether tumor-associated Treg cells arise from the repertoire of
TCRs used by natural Treg cells or from the repertoire used by
effector cells. We show that Treg population in tumors is dominated
by T cells expressing the same TCRs as effector T cells. These data
suggest that Treg in tumors are generated by expansion of a minor
subset of Treg cells that shares TCRs with effector T cells or by
conversion of effector CD4
+ T cells and thus could represent
adaptive Treg cells. In contrast, we found that pre-existing Treg cells,
expressing an exclusive set of TCRs, that dominate in healthy mice
constitute only a small proportion of Treg cells in tumors. We also
demonstrate that immunotherapy aimed at stimulating immune
response does not change proportions of Treg and effector CD4
+ T
cells in tumor-bearing mice.
Methods
Ethics Statement
Full details of the study and all procedures performed on
animals were approved by the Institutional Animal Care and Use
Committee of the Medical College of Georgia (approval number
09-06-213) and complied with all state, federal, and NIH
regulations.
Mice
TCR
mini-Foxp3
GFP miceweregeneratedbycrossing TCR
minimice
expressing restricted TCR repertoire with transgenic mice expressing
Foxp3
GFP reporter transgene [20,22]. TCR
mini mice harbor a mini-
repertoire of TCR a chains encoded by Va2.9 and Ja26 (or Ja2)
associated with one rearranged TCR Vb1 4c h a i n .T h em i c ew e r e
crossed to TCRa chain knockout mice to prevent rearrangements of
endogenous TCRa chains. Thus, the diversity of the TCR repertoire
depends on the CDR3 region of the TCRa chain. Mice expressing a
congenicmarker Ly5.1 werepurchased form Jackson Laboratory(Bar
Harbor, ME) and crossed with transgenic Foxp3
GFP mice. All animals
used were on the C57BL6 background. Mice were maintained in a
specific pathogen-free conditions in a controlled environment which
included filtered air and a 12 hour light/dark cycle. All animals had
free access to food and water.
Tumors
The mouse melanoma cell line B16F1 was obtained from
ATCC. For most experiments B16 melanoma expressing Ep63K
peptide as part of the influenza virus nucleoprotein was used. A
DNA fragment encoding Ep63K peptide (17 amino-acids long)
was introduced between amino acids 264–280 of the nucleopro-
tein (gift of Dr. G. Price) using standard molecular biology
techniques. Modified nucleoprotein (after removal of a stop codon)
was subcloned into pEGFP-N1 vector (EcoRI-SalI sites, SalI site
within Ep63K peptide was mutated during cloning process) to tag
it with green fluorescent protein (GFP) at the C terminus and then
cloned into LZRS-pBMN-Z retroviral vector (between EcoRI and
NotI sites). Retroviral particles were generated as described by
transfecting the Phoenix 293T packaging cell line, a human
embryonic kidney line that produces helper-free ecotropic
retroviruses (provided by Dr. G. Nolan). Retrovirally transduced
cells expressed NP-Ep63K-GFP complexes for at least three weeks
of in vitro culture as assessed by stable GFP expression. To produce
tumors, B16 melanoma cells devoid of or expressing NP-Ep63K-
GFP were sorted and expanded in vitro for 2–3 days before
injection. Tumor cells (5610
4) were injected s.c. in the upper,
inside of both thighs of 6–8 week old TCR
mini-Foxp3
GFP mice and
mice were analyzed after indicated time. Lymph nodes from two
mice were pooled for TCR repertoire analyzes.
Cell purification, flow cytometry and cell sorting
Single-cell suspensions were prepared from lymph nodes by
mechanical disruption and cells were stained with antibodies
available commercially (eBioscience or BD Biosciences). Tumor
infiltrating lymphocytes (TILs) were prepared from tumor lesions
by scrubbing tumor tissue into PBS with 0.1 M EDTA. B16 cell
suspension (10
7 cells/ml) was then overlaid on 5 ml of Lympho-
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at 24uC. The cells at the interphase were collected and, after
washing with HBSS, stained with monoclonal antibodies for flow
cytometry analysis and sorting. Cells were analyzed using
FACSCanto flow cytometer (Becton Dickinson) and FACSDiva
or WinList software. Cells were sorted on a MoFlo cell sorter
(Cytomation). Purity of sorted populations exceeded 98.5%.
Proliferation assay
Proliferation assays were performed with the population of total
CD4
+ T cells or CD4
+Foxp3
GFP- cells sorted from B16 tumors and
tumor-draining lymph nodes. TCR
mini-Foxp3
GFP mice were
inoculated with B16 melanoma expressing NP-Ep63K-GFP
construct (5610
4 injected s.c.) and tumors were allowed to grow
for 2 weeks. Sorted cells (10
5/well) were incubated on a 96-well
plate with irradiated splenocytes devoid of T cells (10
5/well, 3000
Rad) and soluble anti-CD3e (5 mg/ml). Proliferation responses
were measured by adding 1 mCi/well of
3H-thymidine on day 3 of
a 4-day culture.
Two-Dimensional, Fluorescent, Single-Stranded
Conformational Polymorphism Analysis of Va2
Repertoires (2D-F-SSCP)
Analysis of the TCR repertoire using 2D-F-SSCP analysis was
performed on sorted populations of effector and Treg cells from
control, tumor draining lymph nodes and tumor tissues of
TCR
mini-Foxp3
GFP mice injected with melanoma cells as
described previously [22]. Tumor cells were injected s.c. in both
thighs. For analysis brachial and axillary lymph nodes were
considered control lymph nodes, inguinal lymph nodes were
tumor draining lymph nodes. The purity of the sorted populations
exceeded 98%. cDNA prepared from at least 10
5 sorted cells was
used for amplification of the TCRa chains. Fluorescent images
were acquired by scanning the slab gel in a Typhoon 9410 imager
(Amersham-Pharmacia) and analyzed with Image Master 5.0
Platinum software (Amersham-Pharmacia). DNA gels representing
individual cell populations were aligned using control spots of
known DNA sequence added to each sample. DNA for control
spots was selected such that control spots fall outside the gel area
utilized by sample DNA. Spot detection and spot comparison was
accomplished automatically by image analysis software. In a few
cases spots were manually aligned.
Single-cell RT-PCR and TCR sequencing
The populations of naive CD44
2CD62L
+Foxp3
GFP-, activated/
memory CD44
+CD62L
2Foxp3
GFP- and Foxp3
GFPlo and
Foxp3
GFPhi (or all Foxp3
GFP+)T reg CD4
+ cells were sorted from
cell suspensions prepared from control and draining lymph nodes
and tumor infiltrate. For some experiments CD4
+CD25
+ T cells
were sorted from control, draining lymph nodes and tumors. The
purity of the sorted populations exceeded 98%. These populations
were subsequently subjected to single-cell sorting as described
previously [20]. Cells from two TCR
mini-Foxp3
GFP mice were
combined for cell sorting. We analyzed 316, 135, 135 TCRs from
naive, activated and Treg cells from control lymph nodes and 187,
176 and 136 TCRs from the respective populations isolated from
draining lymph nodes. For tumors, 173 and 275 TCRs were
analyzed from activated and Treg cells. DNA sequencing was done
in the DNA sequencing core facility at the University of Illinois.
Cytokine and transcription factor detection by RT-PCR
CD4
+Foxp3
GFP- and CD4
+Foxp3
GFP+ T cells were sorted from
tumors and RNA was isolated with an RNeasy Mini Kit (Qiagen)
and reverse transcribed using a Superscript kit (Invitrogen)
according to the manufacturer’s instructions. b-actin was used to
normalize cDNA quantitiesand wasamplifiedwiththesenseprimer
59CCTTCTACAATGAGCTGCGTGTGGC39 and antisense
primer 59CATGAGGTAGTCTGTCAGGTCC39. Cytokine and
Foxp3 cDNA was amplified using the following primers: Foxp3
sense: 59ATCCAGCCTGCCTCTGACAAGAACC39, antisense:
59GGGTTGTCCAGTGGACGCACTTGGAGC39. These prim-
ers distinguish between amplification product of the endogenous
Foxp3 gene (401 bp) and the transgenic transcript (1357 bp). IL-10,
sense: 59AGTGGAGCAGGTGAAGAGTG39, antisense: 59TTC-
GGAGAGAGGTACAAACG39,T G F - b sense: 59GCTACCAT-
GCCAACTTCTGT39, antisense: 59CGTAGTAGACGATGGG-
CAGT39.
Proliferation inhibition assay
Suppressor function of Foxp3
GFP+ T cells isolated from tumor-
bearing TCR
mini-Foxp3
GFP mice was investigated in the prolifer-
ation inhibition assay. CD4
+Foxp3
GFP- cells (3610
4/well) were
incubated on a 96-well plate with irradiated splenocytes (5610
4/
well, 3000 Rad) and soluble anti-CD3e (5 mg/ml).
CD4
+Foxp3
GFP+ cells (2610
4/well) were sorted from tumor
draining lymph nodes or tumors of TCR
mini-Foxp3
GFP mice,
inoculated two weeks earlier with B16 melanoma tumors, were
added. Cells were sorted using MoFlo sorter, purity of sorted cells
exceeded 98.5%. After 3 day culture proliferation was measured
by adding 1 mCi/well of
3H-thymidine.
Adaptive cell transfer
Donor cells for adaptive transfer were isolated by flow cytometry
sorting of CD4
+Foxp3
GFP- cells from Ly5.1
+/2Foxp3
GFP mice or
CD4
+Foxp3
GFPhi cells from Ly5.1
+/+Foxp3
GFP mice expressing
wild-type TCR repertoires. CD4
+Foxp3
GFP- (2610
6/mouse) and
CD4
+Foxp3
GFPhi cells (3610
5/mouse) were mixed and co-injected
i.v. into recipient Ly5.1
-/- TCR
mini mice. TCR
mini mice were
inoculated with B16 melanoma cells (10
5/mouse s.c.) three days
before cell transfer. Recipient mice were sacrificed 12 days after cell
transfer and cell populations from lymph nodes and tumors were
analyzed by flow cytometry.
Production and immunization with bone marrow-derived
dendritic cells expressing covalent A
bEp63K complex
Bone marrow was isolated from mice expressing A
bEp63K
complex and lacking endogenous wild type A
b molecules and
invariant chain [29]. Bone marrow depleted of erythrocytes was
incubated with granulocyte-macrophage colony stimulating factor
(GM-CSF), and IL-4 (50 units/ml). After 6–7 day culture bone
marrow cells were stained for expression of A
b, CD11c and B7-1.
Cells positive for A
b were sorted with magnetic beads (Miltenyi
Biotech) (purity of sorted cells .98%) and used for immunother-
apy of tumor-bearing C57BL6 Foxp3
GFP mice. C57BL6 Foxp3
GFP
mice (expressing wild type TCR repertoire) were inoculated s.c.
with 5610
4 B16 cells expressing NP-Ep63K. 5610
4 bone marrow-
derived dendritic cells expressing covalently bound complex of
A
bEp63K were co-injected s.c. in the same site at the time of
tumor inoculation. Injections of dendritic cells continued daily
until mice were sacrificed.
Statistical analysis
Diversity of the TCR repertoires was calculated using the Chao
mean estimators of unobserved species with 95% confidence
intervals obtained via bootstrap method based on 10,000
resamples [30]. To assess the similarity between the TCR
Origin of Treg Cells in Tumors
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Leibler distance) for each of the cell subsets against the pooled
‘‘superpopulation’’ consisting of all receptors and pooled relative
frequencies [31]. For a given population repertoire the Kullback-
Leibler distance against the superpopulation was calculated as the
sum of the products between pk and log(pk/qk) where pk denotes the
population frequency of the k-th TCR and qk denotes the pooled
frequency of the k-th TCR (i.e., frequency in the superpopulation).
The Kullback-Leibler distance from the superpopulation was then
bias-corrected by subtracting the estimate of the first order bias
given by (J ˆ21)/(2n) where J ˆ is the Chao mean and n is the
number of all cells in the given population. The confidence
intervals for the bias-corrected Kullback-Leibler distances against
superpopulation were calculated using the bootstrap method with
10,000 resamples. All calculation were done using R software
package.
Results
B16 melanoma expressing Ep63K peptide as a
tumor-associated antigen
We have studied immune response in cancer in TCR
mini-
Foxp3
GFP mice using B16 transplantable tumor model [20].
TCR
mini mice express a naturally generated, polyclonal TCR
repertoire where we can follow the frequency of individual T cell
clones in cell subsets defined by expression of the Foxp3 and
surface markers [20,22]. The relative diversities and the size of
individual clones of CD4
+ T cell subsets in TCR
mini mice are
similar to the natural TCR repertoire as recently determined by
high throughput sequencing of TCRs expressed by human T cells
[32]. The Ep63K peptide is a cognate antigen recognized by the
rearranged TCR that was used to produce TCR
mini mice. The
TCRs specific for Ep63K were identified and their frequency is
known in unmanipulated TCR
mini-Foxp3
GFP mice and in mice
undergoing response to antigen following immunization with
peptide and CFA (Fig. 1A) [20,33]. To take advantage of the
defined TCR repertoire of Ep63K-specific T cells, B16 melanoma
was modified to express this peptide. Since it is generally accepted
that tumor tolerance and immunity are induced by cross-
presentation of tumor antigens, even for class II MHC positive
tumors, we have prepared B16 cells expressing Ep63K peptide as
part of the influenza virus nucleoprotein (NP)(Fig. 1B) [34].
During viral infection, NP expressed in cells lacking MHC class II
molecules, is processed to peptides p260–283 and p413–435,
which bind A
b on antigen presenting cells [35]. A DNA fragment
encoding Ep63K peptide (17 amino-acids long) was introduced
between amino acids 264–280 of the nucleoprotein using standard
molecular biology techniques. The amino acids flanking mutant
peptide p260–283 were preserved in the modified nucleoprotein to
ensure proper proteolytic processing of NP-Ep63K. Modified
protein was tagged with green fluorescent protein and expressed in
B16 melanoma (Fig. 1C). Cross-presentation and processing of
modified nucleoprotein was tested by stimulating Ep63K-specific
hybridoma 123.3 with recombinant NP-Ep63K (Fig. 1D)[36].
Ep63K peptide generated by processing of modified NP
represents antigenic epitope for which immune system is not
tolerant. This class of tumor-associated antigens could potentially
induce more robust immune response than antigenic epitopes
generated by processing of natural, unmutated self proteins and
offers best potential for successful immunotherapy. Recent reports
show remarkable accumulation of mutations by tumor-associated
antigens, including proteins that contribute to the neoplastic
process [37]. Mutant proteins are a source of novel and unique
antigenic epitopes and demonstrate that tumor cells themselves are
a source of a polyvalent vaccine [38]. These new findings suggest
that appropriate manipulation of the immune system could offer
an opportunity to exploit the immunogenicity of the tumors for
cancer immunotherapy.
Analysis of the TCR repertoire in TCR
mini-Foxp3
GFP mice
bearing late stage melanoma tumors reveals expansion
of antigen-specific effector and regulatory CD4
+ T cells
To investigate how populations of CD4
+ effector and Treg cells
change during immune response in cancer and how these two T
cell subsets contribute to the T cell population in the tumor-
draining lymph nodes and tumor tissue, we have followed immune
response to transplantable B16 melanoma. Treg cells are known to
promote growth of B16 melanoma by inhibiting immune
responses to melanoma-associated antigens [12]. B16 melanoma
Figure 1. Amino-acid sequences of TCRa chain CDR3 regions of
Ep63K-specific CD4
+ T cell hybridomas obtained from TCR
mini-
Foxp3
GFP mice and generation of B16 tumors expressing
tumor associated neo-antigen NP-Ep63K. (A) Amino-acid se-
quences of TCRa chain CDR3 regions of Ep63K-specific CD4
+ T cell
hybridomas obtained from TCR
mini-Foxp3
GFP mice. (B) Production of the
nucleoprotein-Ep63K-GFP expression construct. Sections encoding
nucleoprotein are shown as dotted rectangles and GFP is shown as
vertical lines. Parts of the nucleoprotein encoding peptides binding A
b
are shown as clear rectangles and Ep63K peptide is shown as horizontal
lines. Numbers show the range of amino acids constituting peptides
binding to A
b. (C) Flow cytometry analysis of the B16 melanoma cells
expressing nucleoprotein-Ep63K-GFP. B16 melanoma cells were trans-
duced with the LZRS-pBMN-Z retroviral vector expressing nucleopro-
tein-Ep63K-GFP fusion protein (lower histogram) or a control vector
(upper histogram). (D) Recombinant nucleoprotein-Ep63K is processed
by bone marrow derived dendritic cells and Ep63K peptide is
recognized by specific CD4
+ hybridoma 123.3. IL-2 (pg/ml) production
in the supernatant of dendritic cells cultured without and with 0.9 or
1.8 mg/ml of the recombinant protein.
doi:10.1371/journal.pone.0013623.g001
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mini-Foxp3
GFP
mice and CD4
+ T cell populations were analyzed in the control
and tumor-draining lymph nodes and tumors 19 days after tumor
inoculation. Flow cytometry analysis shows increased proportion
of activated cells in the draining lymph nodes and tumors
consistent with the ongoing immune response (Fig. 2A). Increased
proportion of activated T cells is however paralleled by the
concomitant increase of the Foxp3
+ Treg cells. CD4
+Foxp3
GFP+
cells in the tumor draining lymph nodes and tumors express higher
levels of CTLA-4 and GITR than activated Foxp3
GFP- cells
(Fig. 2B). These cells express Foxp3 and high levels of IL-10 and
TGF-b, cytokines known to contribute to the suppressor function
of Treg cells (Fig. 2C). Foxp3
GFP+ cells sorted from B16 tumors are
able to suppress proliferation of effector CD4
+ T cells in vitro
(Fig. 2D). In conclusion, phenotypic and functional analyzes
strongly suggest that CD4
+Foxp3
GFP+ T cells that develop in
melanoma tumors represent genuine Treg cells and not cells
that transiently upregulate Foxp3 without acquiring suppressor
function [39].
To determine the diversity of CD4
+ T cell subsets and assess the
abundance of individual T cell clones, we have used two-
dimensional, fluorescent, single-stranded conformational polymor-
phism (2D-F-SSCP) analysis [22]. TCRa chains were amplified
from naive CD44
2CD62L
+Foxp3
GFP-, activated/memory
CD44
+CD62L
2Foxp3
GFP- and Foxp3
GFPlo and Foxp3
GFPhi Treg
CD4
+ cells sorted from control and draining lymph nodes and
tumor infiltrate (Fig. 3). We have divided Treg population into cells
expressing high and low level of the Foxp3
GFP reporter since they
constitute functionally different Treg subsets in unmanipulated
mice [20]. Fluorescent PCR products of TCRa chains were first
separated according to their length and subsequently according to
their nucleotide sequence. DNA gels representing individual cell
populations were aligned using control spots and pair wise
comparison of gel images was accomplished by analysis software.
The similarity of TCR repertoires was assessed by counting the
numbers of overlapping DNA spots. As shown in Fig. 3, the gels
representing the TCR repertoires of naive cells in the control and
the draining lymph nodes are very similar (72.9% of overlapping
spots) since T cell clones in these subsets are not subject to antigen-
driven selection and expansion. In contrast, the TCR repertoires
of activated and Foxp3
GFPlo and Foxp3
GFPhi Treg cells show
various degree of similarity between anatomical locations. Analysis
of the overlapping spots shows that populations of activated cells in
the draining lymph nodes and tumors are very similar while they
differ from the corresponding population in the control lymph
nodes. Similar relationship was observed for Foxp3
GFPlo and
Foxp3
GFPhi subsets. The TCR repertoires of Foxp3
GFPlo and
Foxp3
GFPhi cells from tumors were more similar to the repertoires
of the respective Treg populations in the draining lymph nodes
than in control lymph nodes. In addition, the TCR repertoires of
activated T cells and Foxp3
GFPlo and Foxp3
GFPhi subsets are more
similar in tumor draining lymph nodes and tumors than in the
control lymph nodes. This suggests that T cell clones from effector
cells are recruited into Treg population in tumor draining lymph
nodes and tumors. To confirm that clones expanded in Treg
populations express the same TCRs as activated T cells, we have
isolated and sequenced spot DNA. The spots corresponding to
the most prominent Ep63K-specific clone are shown on the gel
image representing a population of Treg cells in tumor tissue
(Fig. 3A). In summary, analysis of gel images reveals changes of
TCR repertoires characteristic of the ongoing clonal selection
and expansion and suggests that immune response to tumor-
derived antigens resembles response to conventional antigen
stimulation [40].
Tumor antigen-specific T cell clones expressing the same
TCRs are concurrently expanded in effector and Treg
subsets in the draining lymph nodes and tumor tissue
Analysis of TCR repertoires in mice bearing advanced tumors
shows extensive changes of effector and Treg cells isolated from
various anatomical locations. Populations of activated and Treg
cells have been reshaped as evidenced by clonal expansions and
contractions. The most significant changes affected populations of
Foxp3
GFPlo and Foxp3
GFPhi cells in tumors and included a
significant contribution of Ep63K-specific T cells expressing the
same TCRs as activated effector cells. To further understand and
characterize immune response in cancer, we sought to determine
in what anatomical location and at what stage of the tumor growth
the cellular changes that underlie the failure of immune response
in cancer first occur. We analyzed TCR
mini-Foxp3
GFP mice
bearing early stage, 10 day old B16 tumors. This was the earliest
time when we could isolate sufficient number of cells from tumors.
TCR repertoires were analyzed by sorting single CD4
+ T cells
from populations of naive, activated and Foxp3
GFP+ Treg cells from
control and draining lymph nodes and TILs and by sequencing
TCRa chain genes [20,22]. Naive population was not sorted from
tumor tissue since almost all cells expressed an activated
phenotype. The diversity of TCRs within populations and the
overlap between populations were assessed using Chao mean and
relative entropy index respectively (Fig. 4A, B)[20,22]. The TCR
diversity of naive and activated CD4
+ T cells increased in tumor
draining lymph nodes in comparison to control lymph nodes and
decreased in tumor tissue. Increased diversity in the draining
lymph nodes may reflect recruitment and expansion of T cell
clones associated with inflammatory response in the neighboring
tissues. Further clonal expansion and selection occurred in tumor
tissue and resulted in decreased diversity of the TCR repertoire.
Diversity of TCRs expressed by Treg cells was highest in control
lymph nodes, not subject to antigen stimulation (consistent with
the analysis of unmanipulated mice), and decreased in tumor
draining lymph nodes and in tumors. This suggests that Treg cells
are subject to the most prominent constriction of the TCR
repertoire and further implies that many TCRs expressed in
control lymph nodes (and in healthy mice) will not be present in
tumors (Fig. 4A). Analysis of the TCR repertoire overlap was
conducted to reveal relationship between T cell populations. This
analysis shows that Treg cells in control lymph nodes, that mostly
resemble Treg population in unmanipulated mice, express most
divergent TCR repertoire from all other T cell subsets. In contrast,
Treg cells in tumors and tumor draining lymph nodes are more
similar to activated T cell subsets from the respective anatomic
locations. This suggests that these Treg subsets include higher
proportion of cells expressing the same TCRs as activated cells.
TCR repertoires of activated T cells in control lymph nodes
express intermediate TCR repertoire between activated and Treg
cells from tumor draining lymph nodes and tumors and naive cells.
Both naive cell populations in control and draining lymph nodes
are similar, consistent with the lack of antigen mediated selection
(Fig. 4B). In conclusions, statistical analysis conducted on TCRs
indicates close relationship between activated and Treg cells in
tumor draining lymph nodes and tumors, significant divergence of
Treg cells in control lymph nodes from all other T cell subsets and
close similarity of naive cells in control and tumor draining lymph
nodes.
To examine cellular processes in cancer immune response, we
followed individual T cell clones in populations of naive, activated
and Treg cells in control and draining lymph nodes and in tumors.
Naive cells in control lymph nodes were least affected by the
ongoing anti-tumor response. Single-cell analysis shows a
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13623Figure 2. Flow cytometry, gene expression and functional analysis of effector and Treg cells in TCR
mini-Foxp3
GFP mice bearing B16
melanoma tumors expressing NP-Ep63K. (A) Cells from control, draining lymph nodes and tumor infiltrates were isolated and single cell
suspensions were stained with the relevant antibodies. Expression of Foxp3
GFP (left column) and CD25 (second column) on CD4
+ T cells are shown.
Expression of activation markers CD44 and CD62L is shown on gated effector CD4
+ Foxp3
2 cells (third column) and Foxp3 and CD25 expression are
shown on gated CD4
+ T cells (right column). Gates used to define Foxp3
GFP- cells (left column, continuous line) and subsets of naive CD44
2CD62L
+
(third column, continuous line) and activated CD44
+CD62L
2 (third column, dotted line) cells as well as Foxp3
GFPlo (left column, broken line) and
Foxp3
GFPhi (left column, dotted line) Treg cells for TCR repertoire studies are shown as rectangles. Naive cells were absent in tumors. Figure shows
representative data of at least five mice analyzed. (B) Expression of GITR (left panels) and CTLA-4 (right panels) in CD4
+Foxp3
GFP- (upper panels) and
CD4
+Foxp3
GFP+ (lower panels) cells isolated from tumor draining lymph nodes and tumors. Two individual mice were analyzed. (C) Analysis of Foxp3,
IL-10 and TGF-b expression in Foxp3
GFP- and Foxp3
GFP+ CD4
+ T cells isolated from tumors. Sorted cells were lysed directly and gene expression was
detected by RT-PCR. Samples were normalized for b-actin expression. Two individual mice were analyzed. (D) Foxp3
GFP+CD4
+ T cells isolated from the
draining lymph nodes (DrLN) or tumors (TILs) suppress proliferation of effector CD4
+ T cells. One of two experiments is shown.
doi:10.1371/journal.pone.0013623.g002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13623Figure 3. Analysis of TCR repertoires using 2D-F-SSCP. (A) Spot patterns representing TCR repertoires of naive, activated effector CD4
+ T cells
and Foxp3
GFPlo and Foxp3
GFPhi Treg cells isolated from control and draining lymph nodes and tumors of tumor-bearing TCR
mini-Foxp3
GFP mice. Blue
asterisks indicate control spots used to overlay gel images for analysis. Spots representing T cells expressing the same TCR as Ep63K-specific
hybridoma #274 are shown in the populations of Foxp3
GFPlo and Foxp3
GFPhi cells in tumors. The number of spots defined on each gel by image
analysis software is shown in lower left corner of each gel image. Similarity between gels is shown as percentage of overlapping spots. Gels
compared are indicated by arrows. (B) Pair wise comparison of the total number and number of overlapping spots between naive, activated and Treg
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TCR
mini-Foxp3
GFP mice. Of the 20 most abundant clones in the
population of naive CD4
+ T cells in control lymph nodes of tumor-
bearing mice, 16 were also most abundant in naive cells of
unmanipulated mice (Fig. 5A). T cells expressing these receptors
constituted 69.0 and 70.0% of the respective naive populations.
Similar comparison between the 20 most abundant clones of naive
cells in control and the draining lymph nodes of tumor-bearing
mice shows that only 10 clones were the same in the later
population and they amounted to only 43.3% of all naive cells
(Fig. 5B). Differences in the TCR repertoires of naive T cells in
control and draining lymph nodes are most likely caused by
recruitment of antigen-specific naive cells into draining lymph
nodes before they acquire activation markers.
In contrast to the population of naive cells, TCR repertoires of
activated cells show more pronounced differences between
anatomical locations. Analysis of the twenty most abundant T
cell clones in tumor tissue shows that they account for about
60.0% of activated TILs (Fig. 5C). Six of these clones were also
found in the tumor draining lymph nodes (13.0% of activated T
cells) and fourteen were found in control lymph nodes (20.7% of
activated cells). Thus, not all T cell clones predominating in the
tumors are also present in the tumor draining lymph nodes
suggesting that some tumor-specific T cells may migrate directly to
tumors. The same T cell clones accounted for 2.9% of all Treg cells
in the control lymph nodes, 11.0% of Treg cells in the draining
lymph nodes and 49.5% of Treg cells in the tumor tissue. This
shows increased contribution of effector T cells to the population
of Treg cells. This process is well exemplified by Ep63K-specific T
cells (Fig. 6). The distribution of cells between the populations of
activated and Treg cells varied for individual Ep63K-specific T cell
clones. Three clones (#26, 31, 36) frequently found in control
lymph nodes were also found in the draining lymph nodes,
however we did not observe their clonal expansion. These clones
were also found abundant in unmanipulated mice and did not
expand upon immunization with Ep63K-peptide and CFA [20].
Only one of these clones (#36) was found expanded in tumors
mainly in the population of activated T cells. While two clones
dominate immune response to Ep63K peptide and CFA (#274
and 7), in tumor-bearing mice only one clone (#274) was
abundant in B16 tumors expressing NP-Ep63K [20]. This might
be caused by the differences in the conformation of Ep63K epitope
when it is presented as a soluble peptide or processed from NP-
Ep63K protein. Since clone #274 was also found in B16 tumors
not expressing Ep63K (see below), it is likely that its expansion in
modified tumors resulted from the recognition of both Ep63K and
a natural, unknown epitope produced by melanoma cells. Clone
#274 constituted 5.7 and 0.7% of activated and Treg cells in
draining lymph nodes and 2.9 and 14.9% of activated and Treg
cells in tumors. Thus, this clone is a good example of a major
functional change experienced by effector CD4
+ T cells and while
it constituted about 90.0% of activated and 10.0% of Ep63K-
specific Treg cells in the draining lymph nodes, in tumors it
accounted for only 15.0% of activated and 76.0% of Ep63K-
specific Treg cells. In summary, TCR repertoire analysis suggests
efficient recruitment of tumor-antigen specific cells into tumor
lesions and tumor draining lymph nodes. The initial encounter
with tumor derived antigens most likely occurs in the tumor-
draining lymph nodes where specific clones were first found
expanded. Further expansion occurring in the tumor is associated
with induction of the Foxp3 expression and acquisition of the
suppressor phenotype. Increased contribution of Ep63K-specific
clones to the population of Treg cells in tumors is paralleled by
other CD4
+ T cell clones dominating the population of activated
CD4
+ T cells in tumors. These clones constitute 41.0, 6.7 and
Figure 4. Analysis of the TCR repertoires of naive, activated
and Treg cells in control and draining lymph nodes and tumor
lesions of tumor-bearing TCR
mini-Foxp3
GFP mice. (A) Estimation
of the TCR repertoire diversity using Chao mean. The data range
spanned by vertical lines represent 95% confidence interval for Chao
mean. The circles represent values of Chao estimator. (B) Estimation of
the similarities of the TCR repertoires presented as a dendrogram based
on the differences of the relative entropy against the pooled population
for TCRs expressed by naive, activated (Activ.) and Treg cells isolated
from control (Ctrl. LN) and draining (Dr. LN) lymph nodes and tumor
infiltrate (TILs). The dendrogram construction begins with each cell
subset being a separate cluster. Then, the most similar cell populations
(with the smallest difference in their relative entropies) are joined. We
continue the process until we obtain a single cluster. The distance
between two clusters is taken as the maximum difference in relative
entropies of their members.
doi:10.1371/journal.pone.0013623.g004
CD4
+ T cell populations isolated from control and draining lymph nodes and tumors of tumor-bearing TCR
mini-Foxp3
GFP mice. Left table includes
comparison of cell populations isolated from different anatomical locations, right upper table shows comparisons of cell populations isolated from
the same organ and right lower table shows comparisons of different cell populations isolated from different organs.
doi:10.1371/journal.pone.0013623.g003
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+ T cells and 29.9, 4.7 and 0% of Treg cells
in tumors, tumor draining lymph nodes and control lymph nodes
respectively. Ten TCRs (marked with x) of the twenty that
dominate the population of activated TILs were also found in the
population of CD4
+CD25
+ cells isolated from B16 tumors not
expressing Ep63K epitope (Fig. 5C). Due to limited sampling, the
TCRs we found in B16 tumors expressing and devoid of Ep63K
likely represent only partial overlap of the TCR repertoires. Thus,
analysis of the TCR repertoires of activated and Treg cells in
various anatomic locations shows that both tumor neo-antigen and
natural B16-associated antigens shape the repertoires of CD4
+ T
cell subsets. In conclusion, activation/expansion of effector CD4
+
T cells is associated with the increased proportion of Treg cells
expressing TCRs shared with effector cells in tumors.
We have established that Treg cells expressing TCRs shared
with effector CD4
+ T cells constitute about half of all Treg cells in
the tumor site while in unmanipulated mice they account for only
10-15% of all Treg cells (Fig. 5C)[20]. Most Treg cells in normal
mice, not subjected to antigen stimulation express an exclusive set
of TCRs, different from TCRs expressed by effector T cells, so it
was important to determine the contribution of this subset to the
Treg population in tumors. We have selected twenty Treg clones
most abundant in tumors (account for 72.4% of all Treg cells) and
using our database of TCR sequences collected from unmanip-
ulated and tumor-bearing mice identified clones that express
TCRs shared with naive T cells and TCRs unique for the Treg
cells (Fig. 5D). We found that eleven TCRs expressed by 38.9% of
all Treg cells were also expressed by naive cells and only one TCR
(expressed by 1.1% of Treg cells) was found solely in Treg subset.
Other receptors were not found in the database. The same analysis
conducted on eight Treg clones, with unknown antigen specificity,
shows that TCRs shared with effector CD4
+ T cells (receptor
sequences depicted in black and labeled with N) constitute 18.2%
and 3.7% of all Treg cells in tumors and tumor draining lymph
nodes respectively and are not found in the control lymph nodes.
In summary, Treg cells expressing TCRs shared with effector cells
constitute an increasing proportion of all Treg cells and contribute
to the TCR diversity of these cells.
To further investigate composition of Treg subsets in tumors, we
looked at Treg clones expressing twenty most frequent TCRs
exclusive for Treg cells (Fig. 5E). This set of TCRs accounted for
25.7% of all Treg cells in lymph nodes of unmanipulated mice,
26.0% of Treg cells in the draining lymph nodes of tumor-bearing
mice (10 TCRs found) and for only 2.6% of all Treg cells in tumors
(7 of these TCRs were found). Extending this analysis to all Treg-
specific TCRs, we found that of 79 unique TCRs found in tumor-
draining lymph nodes 48 TCRs belonged to a TCR subset found
exclusively in Treg cells while of 91 unique TCRs found in tumors
only 2 TCRs belonged to this cell subset despite sequencing twice
more receptors from tumor tissue. This surprising result suggests
that Treg cells expressing a unique set of TCRs and predominating
in normal mice have different behavior than Treg cells expressing
TCRs shared with effector T cells present in tumor-bearing mice.
In addition, the most abundant Treg clone expressing a TCR
found only in Treg cells accounted for 1.1% of all Treg cells in
tumors. While we do not know why Treg cells expressing an
exclusive set of TCRs are underrepresented in the tumor infiltrate
with regard to both clonal abundance and TCR diversity, possible
reasons include impaired migration to tumors, inferior expansion
and/or very low frequency of these cells in mice before tumor
Figure 6. Clonal abundance (%) of Ep63K-specific T cell clones
in naive (sparse dots), activated (dense dots) and Treg (stripes)
subsets in the control and draining lymph nodes and tumors of
tumor-bearing TCR
mini-Foxp3
GFP mice. The percentage of all
Ep63K-specific clones in populations of naive, activated and Treg cells
is shown on each plot. Names of hybridomas expressing a particular
TCRa chain are shown above upper panel. Asterisks indicate that no
clones were found in the indicated cell subsets.
doi:10.1371/journal.pone.0013623.g006
Figure 5. Analysis of the TCR repertoire in tumor-bearing TCR
mini-Foxp3
GFP mice. Sequences of the TCRa chain CDR3 regions are shown
below plots, red sequences mark T cell clones specific for Ep63K peptide. Numbers indicate the percentage of clones shown on the plot (black) and
the percentage of the Ep63K-specific cells (red) in the total population of the T cell subset analyzed. (A) Naive CD4
+ T cells in healthy and tumor-
bearing TCR
mini-Foxp3
GFP mice express similar TCR repertoires. Frequencies (%) of the 20 most abundant clones in control lymph nodes of mice with
tumors (dark purple) and in lymph nodes of healthy mice (light purple) are shown. (B) Comparison of TCR repertoires of naive CD4
+ T cells in the
control (dark purple) and the draining lymph nodes (light purple) of TCR
mini-Foxp3
GFP mice with tumors. 20 most abundant clones in the control
lymph nodes is shown. (C) Analysis of frequency of activated (Activ.) and Treg cell clones in control (upper panel) and draining (middle panel) lymph
nodes and tumors (lower panel). 20 most abundant clones in the population of activated T cells in tumors was selected for analysis. TCRs marked with
‘‘x’’ were also found in B16 tumors not expressing Ep63K epitope. (D) The abundance of T cell clones expressing TCRs shared with naive/effector CD4
+
T cells (N) or expressing TCRs exclusive for the Treg subset (R) in the populations of activated (blue, upper part of the panel) and Treg (purple, lower
part of the panel) cells in tumors. Clones selected for analysis are the 20 most abundant clones in the population of Treg cells in tumors. Receptors
found in naive/effector T cells (N) and Treg cells (R) are shown above the plot. Receptors not assigned to any subset are labeled ‘‘?’’. (E) The frequency
of Treg clones (blue) expressing the exclusive set of TCRs in tumors. Clones selected for analysis are the 20 most abundant clones in the population of
Treg cells in healthy mice (purple).
doi:10.1371/journal.pone.0013623.g005
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draining lymph nodes and tumors, sites critical for successful
tumor eradication, is progressively dominated by Treg cells
expressing the same TCRs as effector T cells. In contrast, Treg
cells expressing an exclusive set of TCRs that dominate TCR
repertoires of Treg cells in unmanipulated mice, and even in the
draining lymph nodes of tumor bearing mice constitute dispro-
portionally small fraction of Treg cells in tumors.
Inherent properties of the Treg subsets expressing TCR
shared with effector CD4
+ T cells are responsible for their
dominance in the Treg population in tumors
Analysis of the clonal abundance of Treg cells in TCR
mini-
Foxp3
GFP mice bearing B16 melanoma tumors expressing a
neoantigen led to the conclusion that Treg cells in tumors are
dominated by Foxp3
GFP+ cells expressing TCRs shared with
effector T cells. To complement our experiments, we have
investigated the origin of Treg cell populations expressing a wild-
type diversity of TCRs and generated in B16 tumors not
expressing a neoantigen. CD4
+Foxp3
GFP- and CD4
+Foxp3
GFPhi
cells that could be distinguished by allelic markers Ly5.1
+/2 and
Ly5.1
+/+ were sorted by flow cytometry. Sorted conventional and
Treg populations, expressing reciprocal allelic markers, were mixed
and adaptively transferred into TCR
miniLy5.1
2/2 mice (not
expressing Foxp3
GFP transgene) that were inoculated with B16
melanoma tumors (not expressing a neoantigen). CD4
+Foxp3
GFPhi
cells, that constituted 13% of all transferred T cells, express mostly
TCRs found almost exclusively in the Treg population. Since
TCR
mini mice are not lymphopenic, transferred cells do not
undergo homeostatic expansion leading to spontaneous upregula-
tion of Foxp3 and CD4
+Foxp3
GFP- cells that acquire Foxp3
expression represent adaptive Treg cells generated in response to
self peptides or antigens derived from commensal flora [20,41].
Figure 7 shows analysis of recipient mice that received populations
of CD4
+Ly5.1
+/2Foxp3
GFP- and CD4
+ Ly5.1
+/+Foxp3
GFPhi cells.
Similar result was obtained when conventional and Treg cells
expressing, respectively, Ly5.1
+/+ and Ly5.1
+/2 allelic markers
were transferred. CD4
+Foxp3
GFPhi cells represented 9.5% of
transferred cells and accounted for 31.2% of all Treg cells in lymph
nodes of recipient mice (Fig. 7A). However, the same cells in the
tumors represented only 2.3% of all transferred cells and 4.8% of
Treg cells (Fig. 7B). This low proportion of Treg cells in tumors
originating from the preexisting Foxp3
+ cells is a consequence of
superior recruitment/expansion of CD4
+Foxp3
GFP- cells in the
tumor tissue with simultaneous increase in the proportion of
Foxp3
GFP+ T cells in this subset. This outcome is consistent with
recent reports that the population of Treg cells exhibiting a flexible
phenotype and expressing TCRs shared with effector cells (and
representing adaptive Treg cells) expands much better in response
to antigen stimulation or in lymphopenic mice than Treg cells
expressing an exclusive set of TCRs that are found in Foxp3
GFPhi
population sorted from unmanipulated mice [20,23]. Increased
proportion of Treg cells in melanoma tumors than in peripheral
blood and peritumoral tissue was also reported in melanoma
patients and was attributed to selective migration and/or
expansion of Treg cells in tumors [42]. Both Ep63K-specific
CD4
+ T cells and effector cells with unknown antigen specificity
present in the TCR
mini mice as well as adaptively transferred
CD4
+Foxp3
GFP- cells expressing a wild type diversity of the TCR
repertoire were found dominating the population of Treg cells in
melanoma tumors. In conclusion, inherent properties of Treg cells
expressing TCRs shared with naive T cells like efficient
recruitment, expansion and/or upregulation of Foxp3 are
responsible for the predominance of adaptive Treg cells in tumors.
Immunotherapy with dendritic cells presenting
tumor-associated antigen fails to prevent generation
of adaptive Treg cells in tumor tissue
We reasoned that the overwhelming presence of adaptive Treg
cells in tumors might be caused by suboptimal antigen stimulation
in tumors compared to draining lymph nodes and could be
corrected by immunotherapy. Previous reports showed that
stimulation with limited antigen dose and premature termination
of TCR signaling promotes generation of Treg cells [43,44]. To
improve the ratio of effector and Treg cells, we augmented immune
response to tumor-associated antigen using dendritic cells.
C57BL6 Foxp3
GFP mice (expressing wild type TCR repertoire)
were inoculated with B16 melanoma expressing NP-Ep63K. Bone
marrow-derived dendritic cells expressing covalently bound
complex of A
bEp63K complex were co-injected in the same site
at the time of tumor inoculation [33]. Injections of dendritic cell
continued daily until mice were sacrificed. Dendritic cells
expressing A
bEp63K complex were devoid of wild type A
b
molecule and also lacked invariant chain [45]. Invariant chain
deficiency prevents cleavage of the Ep63K peptide from A
b and
ensures that all class II MHC present one, covalently bound
peptide. This excludes the possibility that some other class II
MHC associated peptides could be recognized by CD4
+ T cells
and result in Treg induction and ensures that both effector and Treg
cells are stimulated against the same antigenic peptide produced
solely by tumor cells. Dendritic cells expressing A
bEp63K complex
were able to stimulate Ep63K-specific CD4
+ T cells isolated from
TCR
mini-Foxp3
GFP mice in vitro or in vivo without significant
increase in the proportion of Treg cells (Fig. 8A). Tumor-bearing
mice were sacrificed after two weeks and T cells from control and
draining lymph nodes and tumor tissue were analyzed by flow
cytometry (Fig. 8B). Mice undergoing dendritic cell therapy had
more CD4
+ T cells in tumor-draining lymph nodes and tumors
and a higher fraction of CD4
+ T cells expressed an activated
phenotype what shows that dendritic cells were effectively
stimulating Ep63K-specific T cells. However, augmented activa-
tion of effector CD4
+ T cells was accompanied by the concomitant
increase in the fraction of Treg cells. In conclusion, stimulation of
tumor antigen-specific effector cells is associated with conversion
and/or expansion of Treg cells specific for the same antigen. This
finding suggests that efficient presentation of antigen might not be
sufficient to favor the generation of activated T cells in the context
of tumor microenvironment.
Discussion
Emerging data suggest that the population of Foxp3
+ Treg cells
is heterogeneous in humans and mice in terms of its origin and
functional properties [19,20,24,26]. However, since the expression
of the cell surface markers may change reflecting different
activation or functional status of a Treg cell, it might be difficult
to follow Treg subsets in the course of immune response. In a
recent report we were able to correlate functional phenotype of
Treg cells with the expression of a TCR [20]. Thus, we could use
the analysis of the TCR repertoire in TCR
mini-Foxp3
GFP mice to
determine the origin and abundance of Treg subsets expressing
TCRs shared with effector T cells and expressing an exclusive set
of TCRs.
Despite recent advances in immunotherapy, Treg cells remain
the major obstacle for successful cancer treatment. It is therefore
important to determine what is the source and cellular
composition of Treg cells in tumors. We investigated Treg
population in tumor-bearing TCR
mini-Foxp3
GFP mice expressing
naturally rearranged, polyclonal TCR repertoire. To our knowl-
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assessment how the origin and antigenic specificity of T cell
populations change in the course of tumor development.
Considering the major impact of Treg cells on cancer pathology,
we have investigated the origin of these cells, anatomical location
where tumor specific Treg cells are first detectable and the stage of
tumor growth when they are first expanded.
To follow tumor antigen-specific CD4
+ T cells, B16 melanoma
was modified to express NP-Ep63K recombinant protein.
Processing of the recombinant protein by antigen presenting cells
generates Ep63K epitope that mimics tumor associated antigens
that arise from mutant, endogenous proteins for which immune
system is not tolerant but which were proposed to be the most
efficient targets for immunotherapy [37,38,46]. The inclusion of
an experimental neoantigen was dictated by multiple reports
showing that tumors naturally produce antigenic epitopes derived
from mutant as well as native proteins. These antigenic epitopes
are able to elicit activation, clonal expansion and acquisition of
effector functions by antigen specific cytotoxic and helper CD4
+ T
cells [47–51]. In conclusion, by using tumor cells expressing a
neoantigen, we facilitate studies how cellular mechanisms are
established that protect tumors from the immune system and result
in the induction of an active tolerance/anergy mediated by Treg
cells [14,52].
Analysis of the TCR repertoires in TCR
mini-Foxp3
GFP mice
bearing B16 tumors expressing NP-Ep63K demonstrates that the
population of Treg cells expressing TCRs shared with naive CD4
+
T cells, and not the Treg cells expressing an exclusive set of TCRs,
constitute a majority of Foxp3
+ Treg cells in tumors. The recent
report and our own data show that the population of peripheral
Foxp3
+ Treg cells in unmanipulated mice is heterogeneous and
includes a subset expressing TCRs shared with effector T cells
[20,23]. Thus, it is not possible to demonstrate whether an
individual Treg cell expressing a shared TCR in tumor-bearing
mice arose from expansion of a cell preexisting in a healthy mouse,
or from an effector T cell converted during tumor antigen-driven
response and thus representing an adaptive Treg cell. This
distinction may not be very meaningful since we have recently
showed that Treg cells in healthy mice expressing shared receptors
resemble adaptive Treg cells [20]. At the population level, most
Figure 7. Adaptive Treg cells expressing wild-type TCR reper-
toire dominate Treg cell population in melanoma tumors.
TCR
mini mice were inoculated with B16 melanoma tumors and, after 3
days, reconstituted with CD4
+Foxp3
GFP- from Ly5.1
+/2Foxp3
GFP mice or
CD4
+Foxp3
GFPhi cells from Ly5.1
+/+Foxp3
GFP mice. Lymph nodes (A) and
tumor infiltrating lymphocytes (B) were analyzed by flow cytometry 12
days after cell transfer. (A) Flow cytometry analysis of the CD4
+ T cell
population in tumor draining lymph nodes. Upper left dot plot shows
Foxp3
GFP expression (dotted line rectangle) in CD4
+ T cells (dashed line
rectangle). Numbers represent proportions of cells in each quadrant.
Lower left dot plot shows proportions of recipient Ly5.1
2/2 T cells and
donor Ly5.1
+/+Foxp3
GFPhi and Ly5.1
+/2Foxp3
GFP- cells in the total
population of gated CD4
+ T cells. Gate used to define CD4
+ T cells is
shown by dashed rectangle on the upper left plot. Proportions of cells
expressing Foxp3
GFP in donor CD4
+Ly5.1
+/+ and CD4
+Ly5.1
+/2 cells are
shown on upper and lower histograms respectively. Upper right dot
plot shows proportions of lymph node CD4
+Foxp3
GFP+ Tc e l l s
generated by donor Ly5.1
+/+Foxp3
GFPhi and Ly5.1
+/2Foxp3
GFP- cells.
Gate used to define CD4
+Foxp3
GFP+ T cells is shown by dotted rectangle
on the upper left dot plot. The data shown is representative of three
mice analyzed. The summary of the data for gated total CD4
+ cells and
CD4
+Foxp3
GFP+ cells is presented on the bar graph. (B) Flow cytometry
analysis of the CD4
+ T cell population in tumors. Lymphoid cells were
purified on Lympholyte-M gradient. All dot plots and histograms show
the same cell subsets as analyzed in the lymph nodes.
doi:10.1371/journal.pone.0013623.g007
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shared TCRs and antigen-driven conversion contribute to the
abundance of the Treg subset expressing TCRs shared with
effector cells. Considering the large size of the population of naive
CD4
+ T cells and a comparably small proportion of Treg cells
expressing shared TCRs, most of Treg cells in tumors are likely
generated by conversion of effector CD4
+ T cells. This view is
supported by evidence of efficient expansion of the preexisting
adaptive Treg cells in immunized mice, adaptive transfer studies
and by published report demonstrating that conversion into Treg
cells is an efficient mechanism of acquiring Foxp3 expression
[53,54].
Conversion and/or expansion of the Treg cells expressing shared
TCRs might be a general feature of response to antigen since these
cells were also demonstrated in the draining lymph nodes of mice
immunized with peptide antigen and CFA [20]. Thus, regardless
of the origin of antigen and possible differences in the mode of
antigen presentation, adaptive Treg cells are generated both in
immunized and tumor-bearing mice. Inflammation caused by
immunization with CFA did not prevent the generation of
adaptive Treg cells. In fact, inflammation was found to be a
contributing factor in many cancers and our data imply that
cancer treatments aimed at stimulating inflammatory reaction in
the site of tumor growth may not promote tumor eradication [55].
Analysis of the frequency of individual Ep63K-specific clones
reveals that the magnitude of clonal expansion might correlate
with the proportion of T cells that acquire Foxp3 expression and
become Treg cells. The major increase in the abundance of
antigen-specific cells occurred for T cells expressing TCRs of
hybridoma #274 that is rarely found in unmanipulated mice but
dominates antigen response to conventional immunization with
peptide antigen and CFA. Another Ep63K-specific clone express-
ing TCR of hybridoma #36 was found modestly expanded in
tumors though it was not expanded upon immunization with
Ep63K-peptide and CFA [20]. In contrast, CD4
+ T cells
expressing TCRs utilized by hybridomas #31 and 26 were not
expanded in tumor draining lymph nodes and tumors. This is
most likely caused by their low affinity for Ep63K since the same
cells also did not respond to immunization with soluble Ep63K
administered with CFA. Analysis of clonal frequencies in tumors
shows that clone #274, that expanded the most, had highest
contribution to the Treg population, clone #36, that expanded
less, had smaller contribution and clones #31 and #26, that did
not expand, were rarely seen in activated and Treg cells in tumors.
The association between antigen-driven clonal expansion and
acquisition of Treg phenotype was seen in cervical cancer patients
and in tumor-bearing mice following vaccination suggesting that it
is likely a general phenomenon associated with antigen stimulation
[56,57]. However, previous studies in a mouse model have relied
on TCR-transgenic T cells that may not reflect the behavior of a
naturally-diverse polyclonal TCR repertoire.
Ep63K-specific CD4
+ T cells undergo efficient clonal expansion
in response to antigen produced by tumor cells. This experimental
system mimics the desired response of the immune system to
Figure 8. Flow cytometry analysis of CD4
+ T cells stimulated with dendritic cells presenting Ep63K peptide. Expression of Foxp3
GFP and
CD25 is shown on gated CD4
+ T cells. (A) Analysis of the CD4
+ T cells from control (left) and draining (middle) lymph nodes of TCR
mini-Foxp3
GFP mice
immunized with dendritic cells presenting Ep63K and CD4
+ T cells isolated from TCR
mini-Foxp3
GFP mice and stimulated with dendritic cells in vitro
(right). Dendritic cells (2610
5) were injected into footpads of TCR
mini-Foxp3
GFP mice for three days and mice were sacrificed after 5 days and popliteal
lymph nodes were analyzed. (B) Analysis of gated CD4
+ T cells isolated from tumors of tumor-bearing TCR
mini-Foxp3
GFP control mice (left) and mice
immunized with dendritic cells (middle). TCR
mini-Foxp3
GFP mice were inoculated with B16 melanoma cells expressing NP-EP63K and at the same time
dendritic cells were injected (5610
4). Injections of dendritic cells continued daily until mice were sacrificed. The abundance (%) of CD4
+ T cells subsets
CD25
-Foxp
GFP+, CD25
+Foxp
GFP+ and CD25
+Foxp
GFP- in the tumor tissue of TCR
mini-Foxp3
GFP control (dots) and immunized (stripes) mice. At least three
mice were analyzed in each group.
doi:10.1371/journal.pone.0013623.g008
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at lower levels or less immunogenic, may not elicit efficient cellular
response. Our data strongly suggest that immunotherapy targeting
this type of antigens by augmenting their antigenicity will have a
similar outcome as the response to a highly immunogenic antigens.
Activation and clonal expansion of effector CD4
+ T cells will result
in the generation of adaptive Treg cells and/or expansion of Treg
cells sharing TCR with effector T cells.
The small contribution of Treg cells (both in terms of TCR
diversity and clonal abundance) expressing an exclusive set of
TCRs and preexisting in healthy mice to the population of Foxp3
+
T cells in tumors is surprising, especially considering that these
cells still constitute a significant proportion of Foxp3
+ Treg cells in
the tumor draining lymph nodes. We do not think it is an artifact
of our experimental approach. Our conclusions are based on the
analysis of single cells that avoids bias that might be introduced by
sequencing TCRs from the library amplified by the PCR. In
addition, analysis of the clonal abundance accounts for over 70%
of all Foxp3
+ T cells in tumor tissues so it is unlikely that we missed
some Treg clones that account for a large fraction of Foxp3
+ cells in
tumors. Treg cells in unmanipulated mice (expressing mainly an
exclusive set of TCRs) consistently had the most diverse TCR
repertoire in several unmanipulated mice analyzed so far, so it is
unlikely that they do not contain tumor-antigen specific cells. We
hypothesize that migration or tissue homing of these cells may be
different from the majority of Treg cells found in tumors. This
interpretation is further supported by the demonstration that Treg
cells expressing an exclusive set of TCRs constitute a significant
fraction of Treg cells in the tumor draining lymph nodes and by the
adaptive transfer experiment showing that Treg cells derived from
transferred effector cells are more efficiently recruited and
expanded in the tumors than Treg cells preexisting in unmanip-
ulated mice. In fact, recent transcriptional analysis of tumor-
derived Treg cells shows that they express a different gene
expression profile than Treg cells in healthy mice [58].
Analysis of early and late stage tumors shows that composition
of the cellular infiltrate does not change with tumor progression. In
contrast, our data show that, at least for the widely used
transplantable tumor model, cellular changes that compromise
the functions of the immune system do not occur following
productive immune response but are evident already at the stage
when tumors are first detectable. Tumor models that progress
through the salient period of preclinical cancer are needed to
investigate how immune response evolves in more natural cancer
models but some preliminary data indicate that it may also be
compromised at the very early stages of cancer [59]. In fact, recent
report demonstrates that Treg cells expand dynamically upon
tumor antigen recognition and create tolerogenic environment in
tumors from the onset of tumor growth [60]. Though, the analysis
of the TCR repertoire of expanded Treg cells was not conducted in
this study, it was shown that at least some Treg cells expressed the
same TCRs as effector T cells.
Our analysis of the immune response in cancer and previously
reported analysis of immune response to peptide antigen
administered with strong adjuvant reveals several common
features [20]. In both cases antigen-specific effector T cells are
efficiently recruited into draining lymph nodes and undergo clonal
expansion. Thus, impaired clonal expansion or lack of it is an
unlikely cause of the failed response in cancer. Another common
feature is that Treg population becomes enriched in cells expressing
TCRs shared with effector cells, either by upregulation of Foxp3 in
effector T cells, or by expansion of a minor Treg subset.
Generation of Treg cells that share TCRs with effector T cells is
not a result of suboptimal stimulation by antigen. In contrast,
augmenting immunization with professional antigen presenting
cells increases generation of both antigen-specific effector and
adaptive Treg cells.
In our model, we show that some adaptive Treg cells can be
generated in the course of a productive immune response, against
antigens presented via conventional immunization. This process
enriches Treg population in cells with the same antigen specificity
as effector cells and would be consistent with the known role of
induced Treg responses in limiting excessive inflammation and
tissue damage [61]. In the case of tumors, it appears that the
natural mechanisms existing to generate or expand Treg cells
during response to conventional antigen become exaggerated and
subverted by tumor cells. This elicits disproportionate production
of Treg cells and shifts the cellular balance from effector helper cells
towards cells with suppressor function in order to avoid immune
system mediated destruction. The outcome of immunization with
dendritic cells expressing the same antigen as tumor cells
demonstrates that even strong stimulation with antigen in the
tumor site still does not shift the balance to favor production of
effector T cells at the expense of Treg cells. This further suggests
that improved cancer immunotherapy may depend on the ability
to block tumor-antigen induced expansion of a minor Treg subset
or generation of adaptive Treg cells, rather than solely on
increasing the immunogenicity of vaccines.
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